PURPOSE: The aim of this study was to investigate the cumulative probability of prostate cancer detection according to free/total prostate-specific antigen (PSA) ratio in men with PSA levels of 2.1-10.0 ng/ml and also likelihood of detecting clinically insignificant prostate cancer in population-based screening. METHODS: A total of 1,277 men aged between 55 and 69 years with total PSA (tPSA) levels of 2.1-10.0 ng/ml screened in population screening in Kanazawa city and underwent systematic transrectal ultrasonography-guided prostate biopsy between 2000 and 2011 were enrolled. The cumulative probability of prostate cancer detection in biopsy according to age, serum tPSA, and free-to-total PSA (f/t PSA) ratio was investigated. The clinicopathological features of screening-detected prostate cancer were also investigated. RESULTS: Of the 1,277 subjects in the study population, 320 (25.0 %) were diagnosed with prostate cancer during the observation period. The probabilities of prostate cancer detection at 3 years were 64.5, 41.2, 28.5, and 14.3 % for the men with f/t PSA ratio ≤0.08, 0.09-0.13, 0.14-0.22, and ≥0.23, respectively; the differences in probabilities of prostate cancer detection among men with different f/t PSA ratios were statistically significant. Among 320 patients, 84 (26.3 %) had favorable clinicopathological features that made them suitable for active surveillance. The f/t PSA ratio in unfavorable cancer patients was significantly lower that that in favorable cancer patients. CONCLUSION: The present study demonstrated that the f/t PSA ratio was a strong predictor of future cancer detection and unfavorable cancerous features in prostate biopsy in men with total PSA levels of 2.1-10.0 ng/ml at population screening.
PURPOSE: The aim of this study was to investigate the cumulative probability of prostate cancer detection according to free/total prostate-specific antigen (PSA) ratio in men with PSA levels of 2.1-10.0 ng/ml and also likelihood of detecting clinically insignificant prostate cancer in population-based screening. METHODS: A total of 1,277 men aged between 55 and 69 years with total PSA (tPSA) levels of 2.1-10.0 ng/ml screened in population screening in Kanazawa city and underwent systematic transrectal ultrasonography-guided prostate biopsy between 2000 and 2011 were enrolled. The cumulative probability of prostate cancer detection in biopsy according to age, serum tPSA, and free-to-total PSA (f/t PSA) ratio was investigated. The clinicopathological features of screening-detected prostate cancer were also investigated. RESULTS: Of the 1,277 subjects in the study population, 320 (25.0 %) were diagnosed with prostate cancer during the observation period. The probabilities of prostate cancer detection at 3 years were 64.5, 41.2, 28.5, and 14.3 % for the men with f/t PSA ratio ≤0.08, 0.09-0.13, 0.14-0.22, and ≥0.23, respectively; the differences in probabilities of prostate cancer detection among men with different f/t PSA ratios were statistically significant. Among 320 patients, 84 (26.3 %) had favorable clinicopathological features that made them suitable for active surveillance. The f/t PSA ratio in unfavorable cancerpatients was significantly lower that that in favorable cancerpatients. CONCLUSION: The present study demonstrated that the f/t PSA ratio was a strong predictor of future cancer detection and unfavorable cancerous features in prostate biopsy in men with total PSA levels of 2.1-10.0 ng/ml at population screening.
Authors: Gerald L Andriole; David L Levin; E David Crawford; Edward P Gelmann; Paul F Pinsky; David Chia; Barnett S Kramer; Douglas Reding; Timothy R Church; Robert L Grubb; Grant Izmirlian; Lawrence R Ragard; Jonathan D Clapp; Philip C Prorok; John K Gohagan Journal: J Natl Cancer Inst Date: 2005-03-16 Impact factor: 13.506
Authors: E David Crawford; Judd W Moul; Kyle O Rove; Curtis A Pettaway; Lois E Lamerato; Alexa Hughes Journal: BJU Int Date: 2011-06-28 Impact factor: 5.588
Authors: Andrew W Roddam; Michael J Duffy; Freddie C Hamdy; Anthony Milford Ward; Julietta Patnick; Christopher P Price; Janet Rimmer; Cathie Sturgeon; Peter White; Naomi E Allen Journal: Eur Urol Date: 2005-09 Impact factor: 20.096
Authors: Christine Bouchardy; Gerald Fioretta; Elisabetta Rapiti; Helena Maria Verkooijen; Charles Henry Rapin; France Schmidlin; Raymond Miralbell; Roberto Zanetti Journal: Int J Cancer Date: 2008-07-15 Impact factor: 7.396
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245
Authors: Salah Alzghoul; Mohammad Hailat; Sandra Zivanovic; Long Que; Girish V Shah Journal: Biosens Bioelectron Date: 2015-10-09 Impact factor: 10.618